| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sonia Minuzzo, Valentina Agnusdei, Marica Pinazza, Adriana A Amaro, Valeria Sacchetto, Ulrich Pfeffer, Roberta Bertorelle, Orietta Spinelli, Valentina Serafin, Stefano Indraccol. Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts. Experimental hematology & oncology. vol 12. issue 1. 2023-09-04. PMID:37667380. |
hence, targeting the notch1 signaling pathway may be an effective option to overcome relapsed and refractory t-all.here, we focused on the therapeutic activity of the notch1-specific monoclonal antibody omp-52m51 in combination either with drugs used during the induction, consolidation, or maintenance phase in mice xenografts established from pediatric and adult relapsed notch1 mutated t-all samples. |
2023-09-04 |
2023-09-07 |
mouse |
| Michele Dal Bo, Maria Ilaria Del Principe, Federico Pozzo, Dario Ragusa, Pietro Bulian, Davide Rossi, Giovanni Capelli, Francesca Maria Rossi, Pasquale Niscola, Francesco Buccisano, Riccardo Bomben, Antonella Zucchetto, Luca Maurillo, Paolo de Fabritiis, Sergio Amadori, Gianluca Gaidano, Valter Gattei, Giovanni Del Poet. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Annals of hematology. vol 93. issue 10. 2015-02-18. PMID:24923451. |
the presence of notch1 mutations identifies a cll subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. |
2015-02-18 |
2023-08-13 |
Not clear |
| Michele Dal Bo, Maria Ilaria Del Principe, Federico Pozzo, Dario Ragusa, Pietro Bulian, Davide Rossi, Giovanni Capelli, Francesca Maria Rossi, Pasquale Niscola, Francesco Buccisano, Riccardo Bomben, Antonella Zucchetto, Luca Maurillo, Paolo de Fabritiis, Sergio Amadori, Gianluca Gaidano, Valter Gattei, Giovanni Del Poet. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Annals of hematology. vol 93. issue 10. 2015-02-18. PMID:24923451. |
notch1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. |
2015-02-18 |
2023-08-13 |
Not clear |